NASDAQ:AKRXAkorn Stock Price, Forecast & News

$0.19

-0.02 (-10.29 %)

(As of 05/27/2020 09:56 AM ET)

Add

Compare

Today's Range

$0.19

Now: $0.19▼

$0.20

50-Day Range

$0.17

MA: $0.24▼

$0.33

52-Week Range

$0.17

Now: $0.19▼

$5.46

Volume86,361 shs

Average Volume20.74 million shs

Market Capitalization$25.09 million

P/E RatioN/A

Dividend YieldN/A

Beta1.15

Akorn, Inc., a specialty generic pharmaceutical company, develops, manufactures, and markets generic and branded prescription pharmaceuticals, over-the-counter (OTC) consumer health products, and animal health pharmaceuticals in the United States and internationally. The company operates in two segments, Prescription Pharmaceuticals and Consumer Health. The Prescription Pharmaceuticals segment offers generic and branded prescription pharmaceuticals in various dosage forms, including sterile ophthalmics, injectables, and inhalants; and non-sterile oral liquids, topicals, nasal sprays, and otics. Its primary products include Akten, a topical ocular anesthetic gel; AzaSite, an antibiotic used to treat bacterial conjunctivitis; Cosopt, Cosopt PF, Betimol, and Zioptan, which are used in the treatment of glaucoma; and Xopenex inhalation solution used in the treatment or prevention of bronchospasm. The Consumer Health segment manufactures and markets OTC products for the treatment of dry eye under the TheraTears brand. It also markets other OTC consumer health products comprising Mag-Ox, a magnesium supplement; and the Diabetic Tussin line of cough and cold products. In addition, this segment offers a portfolio of animal health products, such as Anased and VetaKet veterinary sedatives; Tolazine and Yobine sedative reversing agents; and Butorphic, a pain reliever. Akorn, Inc. was founded in 1971 and is headquartered in Lake Forest, Illinois.

Beat the Market (BTM) Rank^™

3.0 Analyst's Opinion

Consensus Rating
Akorn has received a consensus rating of Hold. The company's average rating score is 2.00, and is based on no buy ratings, 2 hold ratings, and no sell ratings.
Price Target Upside/Downside
According to analysts' consensus price target of $3.00, Akorn has a potential upside of 1,492.4% from its current price of $0.19.
Amount of Analyst Coverage
Akorn has only been the subject of 1 research reports in the past 90 days.

2.7 Community Rank

Outperform Votes
Akorn has received 561 “outperform” votes. (Add your “outperform” vote.)
Underperform Votes
Akorn has received 492 “underperform” votes. (Add your “underperform” vote.)
Community Sentiment
Akorn has received 53.28% “outperform” votes from our community.

MarketBeat's community ratings are surveys of what our community members think about Akorn and other stocks. Vote “Outperform” if you believe AKRX will outperform the S&P 500 over the long term. Vote “Underperform” if you believe AKRX will underperform the S&P 500 over the long term. You may vote once every thirty days.

0.0 Dividend Strength

Dividend Yield
Akorn does not currently pay a dividend.
Dividend Growth
Akorn does not have a long track record of dividend growth.

1.0 Company Ownership

Insider Buying vs. Insider Selling
In the past three months, Akorn insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $41,902.00 in company stock.
Percentage Held by Insiders
Only 3.90% of the stock of Akorn is held by insiders.
Percentage Held by Institutions
64.03% of the stock of Akorn is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

0.6 Earnings and Valuation

Earnings Growth
Earnings for Akorn are expected to grow in the coming year, from ($0.35) to ($0.03) per share.
Price to Earnings Ratio vs. the Market
The P/E ratio of Akorn is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.
Price to Earnings Ratio vs. Sector
The P/E ratio of Akorn is -0.06, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Overall Beat the Market Rank^™

1.47 out of 5 stars

Industry, Sector and Symbol

Stock Exchange NASDAQ

Industry Pharmaceutical preparations

Sub-IndustryPharmaceuticals

SectorMedical

Current SymbolNASDAQ:AKRX

Previous Symbol

CUSIP00972810

CIK3116

Webwww.akorn.com

Phone847-279-6100

Debt

Debt-to-Equity Ratio0.09

Current Ratio0.50

Quick Ratio0.32

Price-To-Earnings

Trailing P/E RatioN/A

Forward P/E RatioN/A

P/E GrowthN/A

Sales & Book Value

Annual Sales$682.43 million

Price / Sales0.04

Cash Flow$0.51 per share

Price / Cash Flow0.37

Book Value($0.15) per share

Price / Book-1.26

Profitability

EPS (Most Recent Fiscal Year)($0.34)

Net Income$-226,770,000.00

Net Margins-55.64%

Return on Equity8.53%

Return on Assets1.31%

Miscellaneous

Employees2,227

Outstanding Shares133,150,000

Market Cap$25.09 million

Next Earnings DateN/A

OptionableOptionable

Receive AKRX News and Ratings via Email

Sign-up to receive the latest news and ratings for AKRX and its competitors with MarketBeat's FREE daily newsletter.

Akorn (NASDAQ:AKRX) Frequently Asked Questions

How has Akorn's stock been impacted by COVID-19 (Coronavirus)?

Akorn's stock was trading at $0.7630 on March 11th, 2020 when COVID-19 reached pandemic status according to the World Health Organization (WHO). Since then, AKRX stock has decreased by 75.3% and is now trading at $0.1884. View which stocks have been most impacted by Coronavirus.

Do Wall Street analysts recommend investors buy shares of Akorn?

2 Wall Street analysts have issued "buy," "hold," and "sell" ratings for Akorn in the last year. There are currently 2 hold ratings for the stock, resulting in a consensus recommendation of "Hold." View analyst ratings for Akorn.

How were Akorn's earnings last quarter?

Akorn, Inc. (NASDAQ:AKRX) posted its earnings results on Monday, May, 11th. The company reported $0.36 earnings per share (EPS) for the quarter, beating the Thomson Reuters' consensus estimate of ($0.09) by $0.45. The business earned $204.69 million during the quarter, compared to the consensus estimate of $168.90 million. Akorn had a positive return on equity of 8.53% and a negative net margin of 55.64%. View Akorn's earnings history.

What price target have analysts set for AKRX?

2 equities research analysts have issued 1-year price objectives for Akorn's stock. Their forecasts range from $2.00 to $4.00. On average, they anticipate Akorn's share price to reach $3.00 in the next twelve months. This suggests a possible upside of 1,492.4% from the stock's current price. View analysts' price targets for Akorn.

Has Akorn been receiving favorable news coverage?

News headlines about AKRX stock have trended somewhat negative this week, according to InfoTrie Sentiment Analysis. The research group identifies negative and positive media coverage by analyzing more than six thousand blog and news sources. The firm ranks coverage of companies on a scale of negative five to positive five, with scores closest to five being the most favorable. Akorn earned a coverage optimism score of -1.0 on InfoTrie's scale. They also gave media coverage about the company a news buzz of 0.0 out of 10, indicating that recent media coverage is extremely unlikely to have an effect on the company's share price in the next few days. View the latest news aboutAkorn.

Are investors shorting Akorn?

Akorn saw a increase in short interest in May. As of May 15th, there was short interest totaling 10,750,000 shares, an increase of 39.1% from the April 30th total of 7,730,000 shares. Based on an average trading volume of 9,290,000 shares, the short-interest ratio is currently 1.2 days. Currently, 9.3% of the shares of the company are short sold. View Akorn's Current Options Chain.

Who are some of Akorn's key competitors?

Some companies that are related to Akorn include Johnson & Johnson (JNJ), Pfizer (PFE), Merck & Co., Inc. (MRK), Eli Lilly And Co (LLY), Bristol-Myers Squibb (BMY), AbbVie (ABBV), Allergan (AGN), Zoetis (ZTS), Horizon Therapeutics (HZNP), Mylan (MYL), Perrigo (PRGO), Jazz Pharmaceuticals (JAZZ), Nektar Therapeutics (NKTR), Pacira Biosciences (PCRX) and Corcept Therapeutics (CORT). View all competitors.

What other stocks do shareholders of Akorn own?

Based on aggregate information from My MarketBeat watchlists, some companies that other Akorn investors own include Celgene (CELG), Integrated Device Technology (IDTI), Skechers USA (SKX), Rite Aid (RAD), Lannett (LCI), Bank of America (BAC), Quantenna Communications (QTNA), Ulta Beauty (ULTA), Paycom Software (PAYC) and Square (SQ).

Who are Akorn's key executives?

Akorn's management team includes the following people:

Mr. Duane A. Portwood, Exec. VP & CFO (Age 53)
Mr. Joseph Bonaccorsi, Exec. VP, Gen. Counsel & Sec. (Age 54)
Mr. Jonathan Kafer, Exec. VP & Chief Commercial Officer (Age 56)
Dr. Bruce Kutinsky, Consultant (Age 53)
Mr. Douglas S. Boothe, Pres, CEO & Direcor (Age 55)

What is Akorn's stock symbol?

Akorn trades on the NASDAQ under the ticker symbol "AKRX."

Who are Akorn's major shareholders?

Akorn's stock is owned by a variety of institutional and retail investors. Top institutional shareholders include BlackRock Inc. (12.32%), State Street Corp (2.36%), AQR Capital Management LLC (1.63%), Two Sigma Advisers LP (1.48%), Invesco Ltd. (1.09%) and Geode Capital Management LLC (1.08%). Company insiders that own Akorn stock include Alan D Weinstein, Christopher Young, Jonathan Kafer, Joseph Bonaccorsi, Steven J Meyer and Terry Allison Rappuhn. View institutional ownership trends for Akorn.

Which institutional investors are selling Akorn stock?

AKRX stock was sold by a variety of institutional investors in the last quarter, including Morgan Stanley, Squarepoint Ops LLC, Two Sigma Investments LP, Geode Capital Management LLC, State Street Corp, BlackRock Inc., Spark Investment Management LLC, and GSA Capital Partners LLP. Company insiders that have sold Akorn company stock in the last year include Christopher Young, and Jonathan Kafer. View insider buying and selling activity for Akorn.

Which institutional investors are buying Akorn stock?

AKRX stock was bought by a variety of institutional investors in the last quarter, including AQR Capital Management LLC, Invesco Ltd., Wells Fargo & Company MN, JPMorgan Chase & Co., and Nuveen Asset Management LLC. Company insiders that have bought Akorn stock in the last two years include Alan D Weinstein, Joseph Bonaccorsi, Steven J Meyer, and Terry Allison Rappuhn. View insider buying and selling activity for Akorn.

How do I buy shares of Akorn?

Shares of AKRX can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.

What is Akorn's stock price today?

One share of AKRX stock can currently be purchased for approximately $0.19.

How big of a company is Akorn?

Akorn has a market capitalization of $25.09 million and generates $682.43 million in revenue each year. The company earns $-226,770,000.00 in net income (profit) each year or ($0.34) on an earnings per share basis. Akorn employs 2,227 workers across the globe.

What is Akorn's official website?

The official website for Akorn is www.akorn.com.

How can I contact Akorn?

Akorn's mailing address is 1925 WEST FIELD COURT SUITE 300, LAKE FOREST IL, 60045. The company can be reached via phone at 847-279-6100 or via email at [email protected]

This page was last updated on 5/27/2020 by MarketBeat.com Staff